Skip to main content
SpringerLink
Log in

Use of Precision Imaging in the Evaluation of Pancreas Cancer

  • Chapter
  • First Online:
Precision Medicine in Cancer Therapy

Part of the book series: Cancer Treatment and Research ((CTAR,volume 178))

Abstract

Pancreas cancer is an aggressive and fatal disease that will become one of the leading causes of cancer mortality by 2030. An all-out effort is underway to better understand the basic biologic mechanisms of this disease ranging from early development to metastatic disease. In order to change the course of this disease, diagnostic radiology imaging may play a vital role in providing a precise, noninvasive method for early diagnosis and assessment of treatment response. Recent progress in combining medical imaging, advanced image analysis and artificial intelligence, termed radiomics, can offer an innovate approach in detecting the earliest changes of tumor development as well as a rapid method for the detection of response. In this chapter, we introduce the principles of radiomics and demonstrate how it can provide additional information into tumor biology, early detection, and response assessments advancing the goals of precision imaging to deliver the right treatment to the right person at the right time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30

    Article  PubMed  Google Scholar 

  2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921

    Article  CAS  PubMed  Google Scholar 

  3. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, Ruiz L, Jariod M, Costafreda S, Coll S, Alguacil J, Corominas JM, Solà R, Salas A, Real FX (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7(5):189–197

    Article  PubMed  Google Scholar 

  4. Manji GA, Olive KP, Saenger YM, Oberstein P (2017) Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res 23(7):1670–1678

    Article  PubMed  Google Scholar 

  5. Chu LC, Goggins MG, Fishman EK (2017) Diagnosis and detection of pancreas cancer. Cancer J 23(6):333–342

    Article  PubMed  Google Scholar 

  6. Sanduleanu S, Woodruff H, de Jong EEC, van Timmeren, Jochems A, Dubois, Lambin E (2018) Tracking tumor biology with radiomics: a systematic review utilizing a radiomics quality score. Radiother Oncol 127:349–360

    Article  PubMed  Google Scholar 

  7. Lubner MG, Smith AD, Sandraesgran K, Sahani DV, Pickhardt PJ (2017) CT texture analysis: applications, biologic correlates, and challenges. RadioGraphics 37:1483–1503

    Article  PubMed  Google Scholar 

  8. Yip S, Aerts HJWL (2016) Applications and limitations of radiomics. Phys Med Biol 61(13):R150–R166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kuo MD, Jamshidi N (2014) Behind the numbers: decoding molecular phenotypes with radiogenomic—guiding principles and technical considerations. Radiology 270(2):320–325

    Article  PubMed  Google Scholar 

  10. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Goggins M (2005) Molecular markers of early pancreatic cancer. J Clin Oncol 23(20):4524–4531

    Article  CAS  PubMed  Google Scholar 

  12. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM (1987) Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47(20):5501–5503

    CAS  PubMed  Google Scholar 

  13. Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W (2015) Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med 15;8(7):11683–11691

    Google Scholar 

  14. Tovar-Camargo OA, Toden S, Goel A (2016) Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers. Expert Rev Mol Diagn 16(5):553–567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Goel A (2015) MicroRNAs as therapeutic targets in colitis and colitis-associated cancer: tiny players with a giant impact. Gastroenterology 149(4):859–861

    Article  PubMed  Google Scholar 

  16. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe’er D, Polyak K, Roberts CW, Siu L, Snyder A, Stower H, Swanton C, Verhaak RG, Zenklusen JC, Zuber J, Zucman-Rossi J (2015) Toward understanding and exploiting tumor heterogeneity. Nat Med 21:846–853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM (2014) Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 20(10):1193–1198

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Herlidou-Même S, Constans JM, Carsin B, Olivie D, Eliat PA, Nadal-Desbarats L, Gondry C, Le Rumeur E, Idy-Peretti I, De Certaines JD (2003) MRI texture analysis on texture test objects, normal brain and intracranial tumors. Magn Reson Imaging 21:989–993

    Article  PubMed  Google Scholar 

  19. Colen RR, Hassan I, Elshafeey N, Zinn PO (2016) Shedding light on the 2016 World Health Organization classification of tumors of the central nervous system in the era of radiomics and radiogenomics. Magn Reson Imaging Clin N Am 24(4):741–749

    Article  PubMed  Google Scholar 

  20. Jamshidi N, Diehn M, Bredel M, Kuo MD (2014) Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 270(1):1–2

    Article  PubMed  Google Scholar 

  21. Pope WB (2015 Feb) Genomics of brain tumor imaging. Neuroimaging Clin 25(1):105–119

    Article  PubMed  Google Scholar 

  22. Yamamoto S, Maki DD, Korn RL, Kuo MD (2012) Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. Am J Roentgenol 199(3):654–663

    Article  Google Scholar 

  23. Yamamoto S, Han W, Kim Y, Du L, Jamshidi N, Huang D, Kim JH, Kuo MD (2015) Breast cancer: radiogenomic biomarker reveals associations among dynamic contrast-enhanced MR imaging, long noncoding RNA, and metastasis. Radiology 275(2):384–392

    Article  PubMed  Google Scholar 

  24. Zhu Y, Li H, Guo W, Drukker K, Lan L, Giger ML, Ji Y (2015) Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma. Sci Rep. 5:17787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Weiss GJ, Ganeshan B, Miles KA, Campbell DH, Cheung PY, Frank S, Korn RL (2014) Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS ONE 9(7):e100244

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Yamamoto S, Korn RL, Oklu R, Migdal C, Gotway MB, Weiss GJ, Iafrate AJ, Kim DW, Kuo MD (2014) ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization Radiology. 272(2):568–576

    PubMed  Google Scholar 

  27. Hayano K, Kulkarni NM, Duda DG, Heist RS (2016) Sahani DV exploration of imaging biomarkers for predicting survival of patients with advanced non-small cell lung cancer treated with antiangiogenic chemotherapy. Am J Roentgenol 206(5):987–993

    Article  Google Scholar 

  28. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K (2012) Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 22(4):796–802

    Article  PubMed  Google Scholar 

  29. Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, Rutman AM, Siripongsakun S, Lu D, Imanbayev G, Kuo MD (2015) A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 62(3):792–800

    Article  PubMed  Google Scholar 

  30. Jiang Han-Yu, Chen Jie, Xia Chun-Chao, Cao Li-Kun, Duan Ting, Song Bin (2018) Noninvasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol 24(22):2348–2362

    Article  PubMed  PubMed Central  Google Scholar 

  31. Jansen RW, van Amstel P, Martens RM, Kooi IE, Wesseling P, de Langen AJ, Menke-Van der Houven van Oordt CW, Jansen BHE, Moll AC, Dorsman JC, Castelijns JA, de Graaf P, de Jong MC (2018) Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget 9(28):20134–20155

    Google Scholar 

  32. Jamshidi N, Jonasch E, Zapala M, Korn RL, Aganovic L, Zhao H, Tumkur Sitaram R, Tibshirani RJ, Banerjee S, Brooks JD, Ljungberg B, Kuo MD (2015) The radiogenomic risk score: construction of a prognostic quantitative, noninvasive image-based molecular assay for renal cell carcinoma. Radiology 277(1):114–123

    Article  PubMed  Google Scholar 

  33. Jamshidi N, Jonasch E, Zapala M, Korn RL, Brooks JD, Ljungberg B, Kuo MD (2016) The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol 26(8):2798–2807

    Article  PubMed  Google Scholar 

  34. Matoori S, Thian Y, Koh D, Sohaib A, Larkin J, Pickering L, Gutzeit A (2017) Contrast-enhanced CT density predicts response to sunitinib therapy in metastatic renal cell carcinoma patients. Transl Oncol. 10(4):679–685

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sala E, Mema SE, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, Weigelt B, Vargas HA (2017) Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol 72(1):3–10

    Article  CAS  PubMed  Google Scholar 

  36. Campbell DH, Barrett M, Ramanathan RK, Von Hoff DD, Korn RL (2014) Quantitative Textural Analysis (QTA) in CT imaging: identifying markers for genetic instability and overall survival in cohort of previously treated metastatic pancreatic cancer (mPC). Cancer Res 74(19 Supplement):1885

    Google Scholar 

  37. Jamshidi N, Korn R, Wu H, Donahue T, Dawson D, Bilow M, Kuo M (2011) Elucidating the radiogenomic landscape of pancreatic adenocarcinoma. In: Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, Nov 26–Dec 2, 2011, Chicago IL

    Google Scholar 

  38. Woolsey JG, Cardenas-Rodriguez JC, Lee JY, Burkett A, Korn RL (2018) Prediction of clinical outcomes for early gastric cancer using radiomic signatures derived from the quantitative texture analysis of conventional CT scans and machine learning. J Clin Oncol 36 (suppl; abstr e16091)

    Article  Google Scholar 

  39. Yoon SH, Kim YH, Lee YJ, Park J, Kim JW, Lee HS, Kim B (2016) Tumor heterogeneity in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer assessed by CT texture analysis: association with survival after trastuzumab treatment. PLoS ONE 11(8):e0161278

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Ng F, Ganeshan B, Kozarski R, Miles KA, Goh V (2013) Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology 266(1):177–184

    Article  PubMed  Google Scholar 

  41. Lubner MG, Stabo N, Lubner SJ, del Rio AM, Song C, Halberg RB, Pickhardt PJ (2015) CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging 40(7):2331–2337

    Article  PubMed  Google Scholar 

  42. Wagner F, Hakami YA, Warnock G, Fischer G, Huellner MW, Veit-Haibach P (2017) Comparison of contrast-enhanced CT and [18F] FDG PET/CT analysis using kurtosis and skewness in patients with primary colorectal cancer. Mol Imaging Biol 19(5):795–803

    Article  CAS  PubMed  Google Scholar 

  43. Ganeshan B, Miles KA, Babikir S, Shortman R, Afaq A, Ardeshna KM, Groves AM, Kayani I (2017) CT-based texture analysis potentially provides prognostic information complementary to interim FDG-PET for patients with Hodgkin’s and aggressive non-Hodgkin’s lymphomas. Eur Radiol 27(3):1012–1020

    Article  CAS  PubMed  Google Scholar 

  44. Penzias G, Singanamalli A, Elliott R, Gollamudi J, Shih N, Feldman M, Stricker PD, Delprado W, Tiwari S, Böhm M, Haynes AM, Ponsky L, Fu P, Tiwari P, Viswanath S, Madabhushi A (2018) Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: preliminary findings. PLoS ONE 13(8):e0200730

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Algohary A, Viswanath S, Shiradkar R, Ghose S, Pahwa S, Moses D, Jambor I, Shnier R, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Purysko AS, Verma S, Ponsky L, Stricker P, Madabhushi A (2018) Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: preliminary findings. J Magn Reson Imaging (Epub ahead of print)

    Google Scholar 

  46. Shiradkar R, Ghose S, Jambor I, Taimen P, Ettala O, Purysko AS, Madabhushi A (2018 May 7) Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: preliminary findings. J Magn Reson Imaging (Epub ahead of print)

    Google Scholar 

  47. Singanamalli A, Rusu M, Sparks RE, Shih NN, Ziober A, Wang LP, Tomaszewski J, Rosen M, Feldman M, Madabhushi A (2016) Identifying in vivo DCE MRI markers associated with microvessel architecture and gleason grades of prostate cancer. J Magn Reson Imaging 43(1):149–158

    Article  PubMed  Google Scholar 

  48. Chaddad A, Kucharczyk MJ, Niazi T (2018) Multimodal radiomic features for the predicting gleason score of prostate cancer. Cancers. 10(8):249–254

    Article  PubMed Central  Google Scholar 

  49. Hanania AN, Bantis LE, Feng ZD et al (2016) Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget 7:85776–85784

    Article  PubMed  PubMed Central  Google Scholar 

  50. Song B, Zhang G, Lu H, Wang H, Zhu W, J Pickhardt P, Liang Z (2014) Volumetric texture features from higher-order images for diagnosis of colon lesions via CT colonography. Int J Comput Assist Radiol Surg 9(6):1021–1031

    Article  PubMed  PubMed Central  Google Scholar 

  51. Hu Y, Liang Z, Song B, Han H, Pickhardt PJ, Zhu W, Duan C, Zhang H, Barish MA, Lascarides CE (2016) Texture feature extraction and analysis for polyp differentiation via computed tomography colonography. IEEE Trans Med Imaging 35(6):1522–1531

    Article  PubMed  PubMed Central  Google Scholar 

  52. Aerts HJ (2016) The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. 2(12):1636–1642

    Article  PubMed  Google Scholar 

  53. Lee JW, Lee SM (2018) Radiomics in oncological PET/CT: clinical applications. Nucl Med Mol Imaging 52(3):170–189

    Article  PubMed  Google Scholar 

  54. Sun R, Limkin EJ, Dercle L, Reuzé S, Zacharaki EI, Chargari C, Schernberg A, Dirand AS, Alexis A, Paragios N, Deutsch É, Ferté C, Robert C (2017) Computational medical imaging (radiomics) and potential for immuno-oncology. Cancer Radiother 21(6–7):648–654

    Google Scholar 

  55. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  CAS  PubMed  Google Scholar 

  56. Srinivasan V, Shobha G (2008) Statistical texture analysis. PWASET 36:1264–1269

    Google Scholar 

  57. Von Hoff DD, Korn RL, Mousses S (2009) Pancreatic cancer—could it be that simple? A different context of vulnerability. Cancer Cell 16:7–8

    Article  CAS  Google Scholar 

  58. Haralick RM (1979) Statistical and structural approaches to texture. Proc IEEE 67:786–804

    Article  Google Scholar 

  59. Galloway M (1975) Texture analysis using gray level run lengths. Comput Graph Image Process 4(2):172–179

    Article  Google Scholar 

  60. Timo O, Pietikainen M, Maenpaa T (2002) Multiresolution gray-scale and rotation invariant texture classification with local binary patterns. IEEE Trans Pattern Anal Mach Intell 24(7):971–987

    Article  Google Scholar 

  61. Drabycz S, Stockwell RG, Mitchell JR (2009) Image texture characterization using the discrete orthonormal S-transform. J digital Imaging 22(6):696–712

    Article  Google Scholar 

  62. Jain AK, Farrokhnia F (1991) Unsupervised texture segmentation using Gabor filters. Pattern Recogn 24(12):1167–1186

    Article  Google Scholar 

  63. Mallat SG (1989) A theory for multiresolution signal decomposition: the wavelet representation. IEEE Trans Pattern Anal Mach Intell 11(7):674–693

    Article  Google Scholar 

  64. Adrien Depeursinge A, Foncubierta-Rodriguez A, Van de Ville D, Müller H (2011) Lung texture classification using locally–oriented Riesz components. In: International conference on medical image computing and computer-assisted intervention. Springer, Berlin, pp 231–238

    Google Scholar 

  65. Stockwell RG, Mansinha L, Lowe RP (1996) Localization of the complex spectrum: the S transform. IEEE Trans Signal Process 44(4):998–1001

    Article  Google Scholar 

  66. Davnall F, Yip CSP, Ljungqvist G, Ng MSF, Sanghera B, Ganeshan B, Miles KA, Cook GJ, Goh V (2012) Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 3(6):573–589

    Article  PubMed  PubMed Central  Google Scholar 

  67. Mackin D, Fave X, Zhang L, Fried D, Yang J, Taylor B, Rodriguez-Rivera E, Dodge KC, Jones AK, Court L (2015) Measuring computed tomography scanner variability of radiomics features. Invest Radiol 50:757–765

    Article  PubMed  PubMed Central  Google Scholar 

  68. Balagurunathan Y, Gu Y, Wang H, Kumar V, Grove O, Hawkins S, Kim J, Goldgof DB, Hall LO, Gatenby RA, Gillies RJ (2014) Reproducibility and prognosis of quantitative features extracted from CT images. Transl Oncol 7:72–87

    Article  PubMed  PubMed Central  Google Scholar 

  69. Balagurunathan Y, Kumar V, Gu Y, Kim J, Wang H, Liu Y, Goldgof D, Hall L, Korn R, Zhao B, Schwartz L, Basu S, Eschrich S, Gatenby R, Gillies R (2014) Test-retest reproducibility analysis of lung CT image features. J Digit Imaging 27:805–823

    Article  PubMed  PubMed Central  Google Scholar 

  70. Bluemke DA, Cameron JL, Hruban RH, Pitt HA, Siegelman SS, Soyer P, Fishman EK (1995 Nov) Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology 197(2):381–385; Ichikawa T, Haradome H, Hachiya J, Nitatori T, Ohtomo K, Kinoshita T, Araki T (1997) Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 202:655–662

    Google Scholar 

  71. Sheridan MB, Ward J, Guthrie JA, Spencer JA, Craven CM, Wilson D, Guillou PJ, Robinson PJ (1999) Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. AJR 173:583–590

    Article  CAS  PubMed  Google Scholar 

  72. Fletcher JG, Wiersema MJ, Farrell MA, Fidler JL, Burgart LJ, Koyama T, Johnson CD, Stephens DH, Ward EM, Harmsen WS (2003) Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology 229:81–90

    Article  PubMed  Google Scholar 

  73. Bronstein YL, Loyer EM, Kaur H, Choi H, David C, DuBrow RA, Broemeling LD, Cleary KR, Charnsangavej C (2004) Detection of small pancreatic tumors with multiphasic helical CT. Am J Roentgenol 182(3):619–623

    Article  Google Scholar 

  74. Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA, Charnsangavej C (2007) Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. Abdom Imaging 32:660–667

    Article  PubMed  Google Scholar 

  75. Chen FM, Ni JM, Zhang ZY, Zhang L, Li B, Jiang CJ (2016) Presurgical evaluation of pancreatic cancer: a comprehensive imaging comparison of CT versus MRI. Am J Roentgenol 206:526–535

    Article  Google Scholar 

  76. Ishigami K, Yoshimitsu K, Irie H, Tajima T, Asayama Y, Nishie A, Hirakawa M, Ushijima Y, Okamoto D, Nagata S, Nishihara Y, Yamaguchi K, Taketomi A, Honda H (2009) Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomography. Eur J Radiol 69:139–146

    Article  PubMed  Google Scholar 

  77. Tamada T, Ito K, N Kanomata, N Sone T, Kanki A, Higaki A, Hayashida M, Yamamoto A (2016) Pancreatic adenocarcinomas without secondary signs on multiphasic multidetector CT: association with clinical and histopathologic features. Eur Radiol 26:646–655

    Article  PubMed  Google Scholar 

  78. Gangi S, Fletcher JG, Nathan MA, Christensen JA (2004) Time interval between abnormalities seen on CT and The clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. Am J Roentgenol 182:897–903

    Article  Google Scholar 

  79. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari St. (2007) Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 102:2157–2163

    Google Scholar 

  80. Ahn SS, Kim MJ, Choi JY, Hong HS, Yong EC, Seok JL (2009) Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol 19:2448–2455

    Article  PubMed  Google Scholar 

  81. Tamada T, Ito K, Kanomata N, Sone T, Kani A, Higaki A, Hayashida M, Yamamoto A (2016) Pancreatic adenocarcinomas without secondary signs on multiphasic multidetector CT: association with clinical and histopathologic features. Eur Radiol 26:646–655

    Article  PubMed  Google Scholar 

  82. Gonoi W, Hayashi TY, Okuma H, Akahane M, Naki Y, Mizuno S, Tateishi R, Isayama H, Koike K, Ohtomoet K (2017) Development of pancreatic cancer is predictable well in advance using contrast enhanced CT: a case-cohort study. Eur Radiol 27(12):4941–4950

    Article  PubMed  Google Scholar 

  83. Bogowicz M, Riesterer O, Sabrina Stark L, Studer G, Unkelbach J, Guckenberger M, Tandini-Lang S (2017) Comparison of PET and CT radiomics for local tumor control in head and neck squanous cell carcinoma. Acta Oncol 56(11):1531–1536

    Article  CAS  PubMed  Google Scholar 

  84. Muraoka N, Uematsu H, Kimura H, Imamura Y, Fujiwara Y, Murakami M, Yamaguchi A, Itoh H (2008) Apparent diffusion coefficient in pancreatic cancer: characterization and histopathological correlations. J Magn Reson Imaging 27:1302–1308

    Article  PubMed  Google Scholar 

  85. Park MJ, Kim YK, Choi SY, Rhim H, Lee WJ, Choi D (2014) Preoperative detection of small pancreatic carcinoma: value of adding diffusion-weighted imaging to conventional MR imaging for improving confidence level. Radiology 273:433–443

    Article  PubMed  Google Scholar 

  86. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M (2013) International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 62(3):339–347

    Article  PubMed  Google Scholar 

  87. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16(20):15–25

    Article  Google Scholar 

  88. Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK (2016 June 10) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 34(17):2010–2019

    Google Scholar 

  89. Borazanci E, Haag S (2017) Chapter 6: Hereditary pancreatic cancer. In: Challenges in pancreatic pathology. ISBN 978-953-51-3116-8. Published April 26, 2017. https://www.intechopen.com/books/challenges-in-pancreatic-pathology

  90. Penheiter AR, Deelchand DK, Kittelson E, Damgard SE, Murphy SJ, O’Brien DR, Bamlet WR, Passow MR, Smyrk TC, Couch FJ, Vasmatzis G, Port JD, Marjańska M, Carlson SK (2018) Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. Pancreatology 18(1):46–53

    Article  CAS  PubMed  Google Scholar 

  91. Fonseca AL, Kirkwood K, Kim MP, Mairta A, Koyay EJ (2018) Intraductal papillary mucinous neoplasms of the pancreas. Current understanding and future directions for stratification of malignancy risk. Pancreas 47:272–279

    Article  PubMed  PubMed Central  Google Scholar 

  92. Hanania AN, Bantis LE, Feng ZD, Wang H, Tamm Ep, Katz MH, Maitra A, Koay KJ (2016) Quantitative imaging to evaluate malignant potential of IPMNs. Oncotarget 7:85776–85784

    Google Scholar 

  93. Olchowy C, Cebulski K, Tasecki M, Chaber R, Olchowy A, Kałwak K, Zaleska-Dorobisz U (2017) The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity—a systematic review. PLoS ONE 12(2):e0171704

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargente D, Ford R, Dancey J, Arbuckh S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Can 45:228–247

    Article  CAS  PubMed  Google Scholar 

  95. Von Hoff DD, Ramanathan RK, Borad MJ, Latheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hildalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29(34):4548–4554

    Article  CAS  Google Scholar 

  96. Conroy T, Desseigne F, Ychou M, Bouche O, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Bhauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med 364:1817–1825

    Article  CAS  PubMed  Google Scholar 

  97. Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Bay RC, Ramanathan RK (2017) 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer. Cancer Imaging 17:23–33

    Article  PubMed  PubMed Central  Google Scholar 

  98. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Natarajan R, Dycter S, Ping J, Shepard M, Devoe CE (2016) Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Canc Res 22(12):2848–2854

    Article  CAS  Google Scholar 

  99. Shukla-Dave A, Lee NY, Jansen JFA, Thaler HT, Stambuk HE, Fury MG, Patel SG, Moreira AL, Sherman E, Karimi S, Wang Y, Kraus D, Shah JP, Pfister DG, Koutcher JA (2012) Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys 82:1837–1844

    Article  PubMed  Google Scholar 

  100. Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ (2012) Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology 264:834–843

    Article  PubMed  Google Scholar 

  101. Zhang H, Tan S, Chen W, Kligerman S, Kim G, D’Souza WD, Suntharalingam M, Lu W (2014) Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol *Biol* Phys 88:195–203

    Article  PubMed  Google Scholar 

  102. Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BDE, Herman JM, Tanguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ (2018) Imaging-based biomarkers: changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer 124(8):1701–1709

    Article  CAS  PubMed  Google Scholar 

  103. Johansen R, Jensen LR, Rydland J, Goa PE, Kvistad KA, Bathen TF, Axelson DE, Lundgren S, Gribbestad IS (2009) Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 29:1300–1307

    Article  PubMed  Google Scholar 

  104. Yip C, Landau D, Kozarski R, Ganeshan B, Thomas R, Michaaelidou A, Goh V (2014) Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiol 270(1):141–148

    Article  Google Scholar 

  105. Smith AD, Gray MR, del Campo SM et al (2015) Predicting overall survival in patients with metastatic melanoma on antiangiogenic therapy and RECIST stable disease on initial posttherapy images using CT texture analysis. AJR Am J Roentgenol 205(3):W283–W293

    Article  PubMed  Google Scholar 

  106. Doumou G, Siddique M, Tsoumpas C, Goh V, Cook G (2015) The precision of textural analysis in 18F-FDG-PET scans of oesophageal cancer. Eur Radiol 25:2805–2812

    Article  PubMed  Google Scholar 

  107. Sandrasegaran K, Lin Y, Asare-Sawiri M, Taiyini T and Tann, M (2018 Aug 16) CT texture analysis of pancreatic cancer. Eur Radiol. https://doi.org/10.1007/s00330-018-5662-1 (Epub ahead of print)

    Article  PubMed  Google Scholar 

  108. Boranzanci EH, Guarnieri C, Haag S, Korn RL, Snyder CE, Hendrickson K, Caldwell D, Von Hoff DD (2018) Retrospective analysis of patients using olaparib (O) in pancreatic cancer (PC). J Clin Oncol 36(4) suppl:389

    Google Scholar 

  109. Chalkidou A, O’Doherty MJ, Marsden PK (2015) False discovery rates in PET and CT studies with texture features: a systematic review. PLoS ONE 10:e0124165

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Bashir U, Siddique MM, Mclean E, Goh V, Cook GJ (2016) Imaging heterogeneity in lung cancer: techniques, applications, and challenges. Am J Roentgenol 207(3):534–543

    Article  Google Scholar 

  111. Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D (2011) Impact of tumor size and tracer uptake heterogeneity in 18F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 52:1690–1697

    Article  PubMed  Google Scholar 

  112. Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, Hindié E, Martineau A, Pradier O, Hustinx R, Perdrisot R, Guillevin R, El Naqa I, Visvikis D (2015) 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 56:38–44

    Article  CAS  PubMed  Google Scholar 

  113. Orlhac F, Soussan M, Maisonobe J-A, Garcia CA, Vanderlinden B, Buvat I (2014) Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med 55:414–422

    Article  CAS  PubMed  Google Scholar 

  114. Velazquez ER, Parmar C, Jermoumi M, Mak RH, van Baardwijk A, Fennessy FM, Lewis JH, De Ruysscher D, Kikinis R, Lambin P, Aerts HJWL (2013) Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Sci Rep. 3:3529

    Article  PubMed  PubMed Central  Google Scholar 

  115. Parmar C, Rios Velazquez E, Leijenaar R, Jermoumi M, Carvalho S, Mak RH, Mitra S, Shankar BU, Kikinis R, Haibe-Kains B, Lambin P, Aerts HJWL (2014) Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS ONE 9:e102107

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  116. Cheng N-M, Fang Y-H, Yen T-C (2013) The promise and limits of PET texture analysis. Ann Nucl Med 27:867–869

    Article  CAS  PubMed  Google Scholar 

  117. Alic L, Niessen WJ, Veenland JF (2014) Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review. PLoS ONE 9:e110300

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D (2012) Reproducibility of Tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med 53:693–700

    Article  PubMed  Google Scholar 

  119. Leijenaar RTH, Carvalho S, Velazquez ER, van Elmpt WJC, Parmar C, Hoekstra OS, Hoekstra CJ, Boellaard R, Dekker ALAJ, Gillies RJ, Aerts HJWL, Lambin P (2013) Stability of FDG-PET radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol 52:1391–1397

    Article  CAS  PubMed  Google Scholar 

  120. Zhou Y, Xie L, Fishman EK (2017) Deep supervision for pancreatic cyst segmentation in abdominal CT scans. arXiv:1706.073462017. Available at: https://arxiv.org/abs/1706.07346. Accessed Sept 29, 2017

Download references

Acknowledgements

The authors would like to acknowledge the generous support of the following Foundations and Granting Agencies: Marley Foundation and NCI U01 grant for early detection of pancreas program at the participating institutions; Virginia G Piper Foundation at HonorHealth for RaDAR program; Senna Magovitz Foundation; SU2C. We would also like to acknowledge Drs. Daniel D. von Hoff M.D. and Haiyang Han Ph.D. for their careful reading of the chapter and to all of the patients and families who have been true warriors in the march toward conquering this disease.

Author information

Authors and Affiliations

  1. Virginia G Piper Cancer Center at HonorHealth, Scottsdale, AZ, USA

    Ronald L. Korn & Erkut Borazanci

  2. Translational Genomics Research Institute, An Affiliate of City of Hope, Phoenix, AZ, USA

    Ronald L. Korn & Erkut Borazanci

  3. City of Hope, Duarte, CA, USA

    Syed Rahmanuddin

  4. Imaging Endpoints Core Lab, Scottsdale, AZ, USA

    Ronald L. Korn

Authors
  1. Ronald L. Korn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Syed Rahmanuddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erkut Borazanci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald L. Korn .

Editor information

Editors and Affiliations

  1. Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, AZ, USA

    Daniel D. Von Hoff

  2. Molecular Medicine Division, Translational Genomics Research Institute, Phoenix, AZ, USA

    Haiyong Han

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Korn, R.L., Rahmanuddin, S., Borazanci, E. (2019). Use of Precision Imaging in the Evaluation of Pancreas Cancer. In: Von Hoff, D., Han, H. (eds) Precision Medicine in Cancer Therapy . Cancer Treatment and Research, vol 178. Springer, Cham. https://doi.org/10.1007/978-3-030-16391-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16391-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16390-7

  • Online ISBN: 978-3-030-16391-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation